Advertisement

Topics

ImmunoGen shares slip after missing Wall Street's 2Q forecasts

07:10 EDT 27 Jul 2018 | Proactive Investors

Revenue of US$9.3mln missed Street estimate as drugmaker was hit by a reduction in fees from licenses and a slowdown in milestone payments

Original Article: ImmunoGen shares slip after missing Wall Street's 2Q forecasts

NEXT ARTICLE

More From BioPortfolio on "ImmunoGen shares slip after missing Wall Street's 2Q forecasts"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...